Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285558 | 0.94 | HRH3 (0.45) | KDM4EHRH3ALDH1A1KMT2AGAA | |
| SCHEMBL4285970 | 0.92 | KDM4E (0.51) | KDM4EHRH3ALDH1A1KMT2AGAA | |
| SCHEMBL4286140 | 0.86 | HCRTR1 (0.44) | KDM4EALDH1A1KMT2ADRD2DRD3 | |
| SCHEMBL3494366 | 0.86 | TEAD1 (0.50) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL4289699 | 0.86 | MAOB (0.45) | ALDH1A1KMT2AMEN1HCRTR1HCRTR2 | |
| SCHEMBL4292747 | 0.86 | KDM4E (0.40) | KDM4EHRH3ALDH1A1KMT2AGAA | |
| SCHEMBL4290686 | 0.85 | ENPP2 (0.43) | ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL4287625 | 0.85 | KDM4E (0.50) | KDM4EHRH3ALDH1A1KMT2A | |
| SCHEMBL4294089 | 0.83 | KDM4E (0.39) | KDM4EALDH1A1KMT2AGAAMEN1 | |
| SCHEMBL4286026 | 0.82 | HPGD (0.49) | KDM4EALDH1A1KMT2AGAADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885HRH3 1248/4885ALDH1A1 388/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885HRH3 1248/4885ALDH1A1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.